1. Jain N, Sharma D, Jain NK. Newer research transforming 24-month treatment of MDR/XDR-TB TO 6 months. Lung India. 2025;42:140–6. https://doi.org/10.4103/lungindia.lungindia_431_24.
2. Michalik M, Lorenc T, Marcinkowski K, Muras M, Mikszta N, Mikszta J, et al. Advances and prospects for treatment strategies of drug-resistant tuberculosis: a review. GMS Hygiene and Infection Control. 2025;20. https://doi.org/10.3205/DGKH000562.
3. Ayenew KD, Habteweld HA, Tsige AW, Bizu YS. Novel Pharmacological Approaches for Multidrug‐Resistant Tuberculosis: Review. Advances in Pharmacological and Pharmaceutical Sciences. 2025;2025:8849786. https://doi.org/10.1155/adpp/8849786.
4. WHO consolidated guidelines on tuberculosis. Module 4: Treatment and care. 2025. https://www.who.int/publications/i/item/9789240107243
5. Saukkonen JJ, Duarte R, Munsiff SS, Winston CA, Mammen MJ, Abubakar I, et al. Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine. 2025;211:15–33. https://doi.org/10.1164/rccm.202410-2096ST.
6. Cross GB. New drugs for the management of tuberculosis. Current Opinion in Infectious Diseases. 2025;38:512–21. https://doi.org/10.1097/QCO.0000000000001156.
7. Minja LT, Van Der Feltz I, Manyama C, Mpagama S, Mhimbira F, Noreña I, et al. Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial. The Lancet Infectious Diseases. 2025;25:1219–29. https://doi.org/10.1016/S1473-3099(25)00289-0.
8. Boubacar Soumana S, Yacouba A, Abdoul Lawi CA, Oumar I, Souleymane B, Soumana A, et al. Evaluation of a short, all oral treatment regimen including bedaquiline, delamanid, linezolid, clofazimine, and pyrazinamide named “Regimen C” for pre-XDR tuberculosis in Niger. Front Tuberc. 2026;3:1718997. https://doi.org/10.3389/ftubr.2025.1718997.
9. Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, Baudin E, et al. Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis. N Engl J Med. 2025;392:468–82. https://doi.org/10.1056/NEJMoa2400327.